Global Hunter Corp. (GBLHF)
Global Hunter’s focus is on strategic and base metals, with an advanced stage copper oxide project in Chile and a highly prospective molybdenum property in British Columbia, Canada. GBLHF teams are working on developing the Corona de Cobre property in Chile and the Rabbit south property in British Columbia.
Molybdenum is alloyed with steel making it stronger and more highly resistant to heat because molybdenum has such a high melting temperature. The alloys are used to make such things as rifle barrels and filaments for light bulbs. The iron and steel industries account for more than 75% of molybdenum consumption.
The two largest uses of molybdenum are as an alloy in stainless steels and in alloy steels-these two uses consume about 60% of the molybdenum needs in the United States. Stainless steels include the strength and corrosion-resistant requirements for water distribution systems, food handling equipment, chemical processing equipment, home, hospital, and laboratory requirements. Alloy steels include the stronger and tougher steels needed to make automotive parts, construction equipment, gas transmission pipes.
Other major uses as an alloy include: Tool steels, for things like bearings, dies, machining components; cast irons, for steel mill rolls, auto parts, crusher parts; super alloys for use in furnace parts, gas turbine parts, chemical processing equipment.
Global Hunter Corp. (GBLHF.PK) is pleased to announce initial assay results from its previously announced surface sampling program. The results are encouraging with new gold showings as well as very positive copper oxide assays over wide-spread areas.
Highlights of the entire program
9 mineralized shear and/or alteration zones sampled total of 13.5 kilometers of strike length along know copper bearing shear and alteration zones tested with 205 rock chip samples
Good grades of soluble copper (oxide) over a significantly large area have been identified; however they represent only about 50% of the total copper grade indicating a mixed oxide-sulphide zone. Numerous iron oxide structures have also been mapped but no iron assays have been received to date.
The Company is planning to re-assay samples for iron to determine if iron is present in significant quantities to represent another target.
Molybdenum also is an important material for the chemicals and lubricant industries. Molybdenum has uses as catalysts, paint pigments, corrosion inhibitors, smoke and flame retardants, dry lubricant (molybdenum disulfide) on space vehicles and resistant to high loads and temperatures. As a pure metal, molybdenum is used because of its high melting temperatures (4,730 F.) as filament supports in light bulbs, metal-working dies and furnace parts. Molybdenum cathodes are used in special electrical applications. It can also be used as a catalyst in some chemical applications.
Global Hunter’s focus is on strategic and base metals, with an advanced stage copper oxide project in Chile and a highly prospective molybdenum property in British Columbia, Canada. GBLHF exploration and development teams are on the ground rapidly advancing the La Corona de Cobre property near La Serena, Chile and the Rabbit South property in British Columbia, Canada. Either one of these projects could carry the company forward on a stand-alone basis, but together they bring the company additional stability, strength and value.
For more information, please visit their website: http://www.globalhunter.ca/
*********************************
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced the presentation of new data that underscore the severity of paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder. PNH is characterized by chronic, uncontrolled complement activation leading to hemolysis (red blood cell destruction), which is measured by the presence of higher than normal levels of lactate dehydrogenase (LDH) through routine laboratory testing.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products for treating patients with severe and life-threatening disease states in the United States, Europe, Latin America, Japan, and the Asia Pacific.
*********************************
ZOLL Medical Corporation (Nasdaq:ZOLL), a manufacturer of medical devices and related software solutions, announced that the Centers for Medicare and Medicaid Services (CMS) Durable Medical Equipment Medical Administrative Contractors (DME MACs) reaffirmed the current coverage policy across all indications for the LifeVest® Wearable Defibrillator.
ZOLL Medical Corporation develops and markets medical devices and related software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies.
*********************************
Amgen Inc. (NASDAQ:AMGN) announced that its Board of Directors declared a $0.36 per share dividend for the first quarter of 2012. This represents an approximate 29 percent increase from that paid in the previous two quarters. The dividend will be paid on March 7, 2012 to all stockholders of record as of the close of business on Feb. 15 , 2012.
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada.
********************************************************************
Signup for FREE Daily Stock Alerts From http://www.CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
